首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1626599

2024 年至 2031 年微流控市場（按產品、應用、最終用戶和地區劃分）

Microfluidics Market By Product (Device, Component Chip Sensor), Application (IVD, POC), End-User (Pharmaceutical, Hospital), & Region for 2024-2031

出版日期: 2024年11月09日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

微流控市場評估 - 2024-2031

對即時診斷測試的需求不斷增長，推動了微流體技術的採用。精準流體操作增強藥物發現和市場開發過程將推動市場規模從 2024 年的 416.3 億美元增至 2031 年的約 1,994.2 億美元。

此外，個人化醫療的日益增長的需求也刺激了微流體技術的應用。微流體系統減少了實驗室和臨床環境中的試劑消耗和營運成本，推動市場在 2024 年至 2031 年期間以 23.86% 的複合年增長率成長。

微流體市場定義/概述

微流體技術是指在微米尺度上操縱和控制流體的科學和技術。該領域涉及能夠處理微量液體（如微升和納升）的設備的設計和製造。微流體系統利用通道、閥門和泵浦來精確管理流體流動，從而實現多個產業的廣泛應用。

微流體技術最重要的應用之一是在生物醫學領域，尤其是診斷和藥物傳輸。微流體設備有助於快速有效地分析血液和唾液等生物樣本，從而實現更早的疾病檢測和個人化醫療。它們還用於將多種測試功能整合到單一晶片上的晶片實驗室系統，大大提高了醫療測試的速度和準確性。

對即時診斷（POC）的需求不斷增長將如何促進微流體技術的採用？

對即時診斷（POC）的需求不斷增長是微流體市場發展的主要驅動力。微流體技術可實現快速、便攜且經濟高效的診斷解決方案，使其成為醫療保健環境中 POC 應用的理想選擇。根據美國國立衛生研究院的數據，預計2022年全球POC診斷市場價值將達到293億美元，預計將快速成長。這種成長是由對快速且準確的診斷工具的需求所推動的，特別是在資源有限的環境中。近日，雅培實驗室宣佈推出全新ID NOW™ COVID-19檢測，該檢測利用微流控技術，最快五分鐘即可得出結果，展示了微流控在快速診斷方面的潛力。

製藥業向個人化醫療的轉變正在推動微流體市場的發展。微流體設備在藥物發現、開發和測試中非常有用，因為它們可以精確控制少量流體。美國食品藥物管理局（FDA）在2022年核准了34種個人化藥物，佔當年所有新藥核准的34%。這項統計數據凸顯了個人化醫療日益增長的重要性。順應這一趨勢，丹納赫集團旗下的 Molecular Devices 公司最近推出了 QPix™ 微生物菌落篩選器，該設備採用微流體技術來增強藥物研發過程。

器官晶片技術的進步正在推動微流體市場的發展。這些微流體裝置模擬人體器官的生理條件，為傳統細胞培養和動物測試提供了更精確的替代方法。美國國家轉化科學促進中心報告稱，自 2012 年以來，該中心已在組織晶片研究上投資超過 2 億美元，凸顯了這項技術的重要性。針對這一最新趨勢，Emulate, Inc. 最近推出了 Brain Chip，這是一種模擬人類血腦屏障的微流體設備。

微流體終端用戶產業的需求波動會抑制市場成長嗎？

微流體市場面臨著與設計和製造複雜設備相關的高昂開發成本的課題。創建精確的微流體系統通常需要先進的材料和製造技術，這可能會很昂貴。這些成本阻礙了小型企業和新創公司進入市場，從而減少了競爭和創新。

監管障礙也是一個重大障礙，尤其是在醫療和製藥領域。用於診斷和藥物輸送的微流體設備必須符合衛生當局製定的嚴格法規和標準。冗長的審批流程會延遲產品的發佈、增加製造商的成本，並且難以跟上快速的技術變更。

終端用戶產業的需求波動也可能影響微流體市場的成長。研究資金、醫療保健需求和工業應用的波動可能導致對微流體產品的需求不一致。經濟衰退和優先事項的轉變將導致投資減少，從而進一步加劇該領域製造商和開發商的市場穩定。

PerkinElmer Inc.（美國）
Beckton Dickinson and Company（美國）安捷倫科技公司（美國） Bio-Rad Laboratories, Inc.（美國）
F. Hoffmann-La Roche Ltd.（瑞士）
丹納赫集團（美國） Illumina 公司（美國） Fluidigm 公司（瑞士）雅培實驗室（美國） Dolomite Microfluidics（英國）
派克漢尼汾公司（美國）

第 11 章市場展望與機會

新興技術
未來市場趨勢
投資機會

第 12 章附錄

縮寫列表
來源與參考文獻

簡介目錄

Product Code: 26660

Microfluidics Market Valuation - 2024-2031

Increasing demand for point-of-care testing is propelling the adoption of microfluidics. Enhanced drug discovery and development processes benefit from precise fluid manipulation is driving the market size surpass USD 41.63 Billion valued in 2024 to reach a valuation of around USD 199.42 Billion by 2031.

In addition to this, rising need for personalized medicine is spurring up the adoption of microfluidics. Microfluidic systems reduce reagent consumption and operational costs in laboratories and clinical settings, this is enabling the market grow at a CAGR of 23.86% from 2024 to 2031.

Microfluidics Market: Definition/ Overview

Microfluidics refers to the science and technology of manipulating and controlling fluids at the micrometer scale. This field involves the design and fabrication of devices that can handle very small volumes of liquids, often in the range of microliters or nanoliters. Microfluidic systems utilize channels, valves, and pumps to precisely manage fluid flow, enabling a wide range of applications across various industries.

One of the most significant applications of microfluidics is in the biomedical field, particularly for diagnostics and drug delivery. Microfluidic devices can facilitate rapid and efficient analysis of biological samples, such as blood or saliva, allowing for early disease detection and personalized medicine. Additionally, they are used in laboratory-on-a-chip systems that integrate multiple laboratory functions into a single chip, greatly enhancing the speed and accuracy of medical testing.

How Growing Demand for Point-Of-Care (POC) Diagnostics Increase Adoption of Microfluidics?

The growing demand for point-of-care (POC) diagnostics has been a significant driver of the Microfluidics Market. Microfluidic technologies enable rapid, portable, and cost-effective diagnostic solutions, making them ideal for POC applications in healthcare settings. According to the National Institutes of Health, the global POC diagnostics market was valued at $29.3 billion in 2022 and is expected to grow rapidly. This growth is fueled by the need for quick and accurate diagnostic tools, especially in resource-limited settings. Recently, Abbott Laboratories announced the launch of their new ID NOW(TM) COVID-19 test, which utilizes microfluidic technology to deliver results in as little as 5 minutes, demonstrating the potential of microfluidics in rapid diagnostics.

The pharmaceutical industry's shift towards personalized medicine has boosted the Microfluidics Market. Microfluidic devices enable precise control over small volumes of fluids, making them invaluable for drug discovery, development, and testing. The U.S. Food and Drug Administration (FDA) approved 34 personalized medicines in 2022, accounting for 34% of all new drug approvals that year. This statistic underscores the growing importance of tailored therapeutics. In line with this trend, Danaher Corporation's subsidiary, Molecular Devices, recently introduced the QPix(TM) Microbial Colony Picker, which incorporates microfluidic technology to enhance drug discovery processes.

Advancements in organ-on-a-chip technology have propelled the Microfluidics Market forward. These microfluidic devices mimic the physiological conditions of human organs, offering a more accurate alternative to traditional cell cultures and animal testing. The National Center for Advancing Translational Sciences reported that it has invested over USD 200 Million in tissue chip research since 2012, highlighting the significance of this technology. Responding to this growing field, Emulate, Inc. recently launched their Brain-Chip, a microfluidic device that models the human blood-brain barrier, potentially revolutionizing drug development for neurological disorders.

Will Fluctuating Demand from End-User Industries of Microfluidics Restraining the Market Growth?

The microfluidics market encounters challenges due to high development costs associated with designing and fabricating complex devices. Creating precise microfluidic systems often requires advanced materials and manufacturing techniques, which can be expensive. These costs can deter smaller companies and startups from entering the market, leading to reduced competition and innovation.

Regulatory hurdles also present a significant restraint, particularly in the medical and pharmaceutical sectors. Microfluidic devices used for diagnostics and drug delivery must comply with stringent regulations and standards set by health authorities. The lengthy approval processes can delay product launches and increase costs for manufacturers, making it difficult for them to keep pace with rapid technological advancements.

Also, fluctuating demand from end-user industries can impact the growth of the microfluidics market. Variations in research funding, healthcare needs, and industrial applications can lead to inconsistent demand for microfluidic products. Economic downturns or shifts in priorities can result in decreased investments, further complicating market stability for manufacturers and developers in this field.

Category-Wise Acumens

Which Factors are Contributing to Device Segment Dominance in Microfluidics Market?

The device segment has emerged as the dominant force in the microfluidics market, driven by the increasing adoption of point-of-care diagnostic devices and lab-on-a-chip systems. These microfluidic devices offer rapid, portable, and cost-effective solutions for various applications in healthcare, research, and environmental monitoring. According to the National Institutes of Health, the global market for microfluidic devices in healthcare was valued at $15.7 billion in 2022 and is projected to grow significantly. Recently, Danaher Corporation's subsidiary, Cepheid, announced the launch of their new GeneXpert Omni system, a portable molecular diagnostics platform utilizing microfluidic technology for rapid testing in remote settings.

In the pharmaceutical industry, microfluidic devices are revolutionizing drug discovery and development processes. These devices enable high-throughput screening, precise drug delivery, and personalized medicine applications. The U.S. Food and Drug Administration reported that in 2023, approximately 25% of all new drug approvals utilized microfluidic technologies in their development process. Addressing this trend, Thermo Fisher Scientific recently introduced their new Gibco CTS Rotea Counterflow Centrifugation System, which incorporates microfluidic technology for cell therapy manufacturing, demonstrating the growing importance of microfluidic devices in advanced therapeutic development.

Which Factors Enhance the Use of Microfluidics in In Vitro Diagnostics (IVD)?

The in vitro diagnostics (IVD) segment is a dominant force in the microfluidics market, driven by the increasing demand for rapid, accurate, and cost-effective diagnostic solutions. Microfluidic technologies enable the miniaturization and automation of complex diagnostic procedures, leading to improved efficiency and reduced sample volumes. According to the U.S. Food and Drug Administration, the number of approved IVD devices utilizing microfluidic technology increased by 35% between 2020 and 2023, highlighting the growing adoption of this technology in diagnostics. Recently, Roche Diagnostics announced the launch of their cobas(R) pure integrated solutions system, which incorporates microfluidic technology to provide high-speed, compact clinical chemistry and immunoassay testing.

The COVID-19 pandemic has significantly accelerated the growth of the IVD segment in the Microfluidics Market, with a particular focus on rapid point-of-care testing. Microfluidic-based diagnostic devices have played a crucial role in the global response to the pandemic by enabling quick and accurate detection of SARS-CoV-2. The World Health Organization reported that as of December 2023, over 60% of approved rapid COVID-19 tests utilized microfluidic technologies. In response to this demand, Abbott Laboratories expanded their ID NOW(TM) platform, introducing new tests for influenza A & B, strep A, and RSV, all leveraging microfluidic technology for rapid results at the point of care.

Country/Region-wise Acumens

Will Early Adoption of Technologies in North America Drive Microfluidics Market Growth?

The North American microfluidics market has been experiencing rapid growth in recent years, driven by advancements in healthcare technology and increasing demand for point-of-care diagnostics. According to the National Institutes of Health (NIH), as of 2022, the U.S. government has invested over USD 500 Million in microfluidics research and development over the past decade. This substantial funding has fueled innovation and accelerated the adoption of microfluidic technologies across various industries, including pharmaceuticals, biotechnology, and environmental monitoring.

The market's expansion is further propelled by the rising prevalence of chronic diseases and the need for more efficient and cost-effective diagnostic solutions. A report from the U.S. Food and Drug Administration (FDA) in 2023 revealed that microfluidic-based diagnostic devices have shown a 30% reduction in time-to-result compared to traditional methods. This improved efficiency has led to increased interest from both healthcare providers and patients, driving market growth. Additionally, the COVID-19 pandemic has heightened awareness of the importance of rapid, accurate diagnostic tools, further boosting the adoption of microfluidic technologies.

Will Burgeoning Pharmaceutical and Biotechnology Industries Enhance Adoption of Microfluidics in Asia Pacific?

The Asia-Pacific region is emerging as a dominant force in the microfluidics market, driven by rapid technological advancements, increasing healthcare expenditure, and growing research activities. Countries like China, Japan, and South Korea are at the forefront of microfluidics adoption in various applications, including diagnostics, drug discovery, and environmental monitoring. According to the World Health Organization, healthcare spending in the Asia-Pacific region increased by 6.3% annually between 2018 and 2022, outpacing global averages. Recently, Danaher Corporation announced the expansion of its microfluidics research and development center in Singapore, highlighting the region's growing importance in the global microfluidics landscape.

The burgeoning pharmaceutical and biotechnology industries in Asia-Pacific have significantly contributed to the region's dominance in the microfluidics market. Microfluidic technologies are increasingly being utilized in drug discovery processes and personalized medicine applications. The China National Medical Products Administration reported that the number of innovative drug approvals in China increased by 40% from 2020 to 2023, with a significant portion utilizing microfluidic technologies in their development. Addressing this trend, Thermo Fisher Scientific recently launched a new microfluidic-based single-cell sequencing platform in collaboration with Chinese researchers, aimed at accelerating genomic studies and drug discovery efforts in the region.

Competitive Landscape

The microfluidics market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the microfluidics market include:

Abbott Laboratories
Roche Diagnostics
Illumina, Inc.
Thermo Fisher Scientific
Agilent Technologies
PerkinElmer, Inc.
Bio-Rad Laboratories
Beckman Coulter, Inc.
RainDance Technologies
Fluidigm Corporation
Elveflow
Siemens Healthineers
Micronit Microfluidics

10X Genomics

uFluidics
Dolomite Microfluidics
Aline Biosciences
Luminex Corporation
Syrris Ltd.
Celerion

Latest Developments

In October 2023, a consortium of biotech companies announced a collaboration to enhance microfluidic chip technologies for rapid diagnostic applications, aiming to improve disease detection and patient outcomes.
In September 2023, researchers at a leading university unveiled a breakthrough in microfluidic systems that allows for real-time monitoring of biochemical reactions, potentially revolutionizing laboratory processes.